PE20221169A1 - Uso de un abridor de canal de potasio kv7 para tratar el dolor - Google Patents

Uso de un abridor de canal de potasio kv7 para tratar el dolor

Info

Publication number
PE20221169A1
PE20221169A1 PE2022001015A PE2022001015A PE20221169A1 PE 20221169 A1 PE20221169 A1 PE 20221169A1 PE 2022001015 A PE2022001015 A PE 2022001015A PE 2022001015 A PE2022001015 A PE 2022001015A PE 20221169 A1 PE20221169 A1 PE 20221169A1
Authority
PE
Peru
Prior art keywords
pain
compound
potassium channel
administration
methods
Prior art date
Application number
PE2022001015A
Other languages
English (en)
Spanish (es)
Inventor
Jr James Philip Johnson
Gregory N Beatch
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of PE20221169A1 publication Critical patent/PE20221169A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Guides In General And Applications Therefor (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
PE2022001015A 2019-12-06 2020-12-04 Uso de un abridor de canal de potasio kv7 para tratar el dolor PE20221169A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US201962948010P 2019-12-13 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (1)

Publication Number Publication Date
PE20221169A1 true PE20221169A1 (es) 2022-07-25

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001015A PE20221169A1 (es) 2019-12-06 2020-12-04 Uso de un abridor de canal de potasio kv7 para tratar el dolor

Country Status (14)

Country Link
EP (1) EP4069211A1 (enExample)
JP (1) JP2023504166A (enExample)
KR (1) KR20220113411A (enExample)
CN (1) CN114786658A (enExample)
AU (1) AU2020397173A1 (enExample)
BR (1) BR112022010733A2 (enExample)
CA (1) CA3159436A1 (enExample)
CL (1) CL2022001477A1 (enExample)
CR (1) CR20220318A (enExample)
IL (1) IL293504A (enExample)
MX (1) MX2022006877A (enExample)
PE (1) PE20221169A1 (enExample)
TW (1) TW202133847A (enExample)
WO (1) WO2021113757A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US7553858B2 (en) * 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
MA52569B1 (fr) * 2018-05-11 2023-11-30 Xenon Pharmaceuticals Inc Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant

Also Published As

Publication number Publication date
WO2021113757A1 (en) 2021-06-10
AU2020397173A1 (en) 2022-06-23
EP4069211A1 (en) 2022-10-12
CN114786658A (zh) 2022-07-22
KR20220113411A (ko) 2022-08-12
TW202133847A (zh) 2021-09-16
CA3159436A1 (en) 2021-06-10
BR112022010733A2 (pt) 2022-08-23
CR20220318A (es) 2022-10-07
MX2022006877A (es) 2022-07-11
CL2022001477A1 (es) 2023-04-28
JP2023504166A (ja) 2023-02-01
IL293504A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
CR20250458A (es) Composiciones para inducir la hidrólisis de ras gtp y sus usos
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
ECSP088762A (es) Tratamiento del dolor
MX2023009314A (es) Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.
MX2020010676A (es) Derivados de pladeniolida como agentes dirigidos al espliceosoma para tratar el cancer.
MX2022013174A (es) Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.
CR20220250A (es) Métodos para el tratamiento de trastornos depresivos
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
MX2024008562A (es) Métodos para tratar o reducir el riesgo de rechazo del trasplante
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2024015077A (es) Benzopirimidina-4(3h)-onas como inhibidores de pi3k
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2024014419A (es) Peptidos y metodos para usar en el tratamiento del dolor
CL2022001477A1 (es) Uso de un abridor de canal de potasio kv7 para tratar el dolor
EA202190753A1 (ru) Состав, содержащий озонированное масло, для лечения опухоли
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
BR112022009794A2 (pt) Método para tratar câncer no pulmão
MX2021011263A (es) Uso de moduladores del receptor gabaa para el tratamiento del dolor.
AR071779A1 (es) Formulaciones de emulsion narcotica para el tratamiento del dolor quirurgico
MX2023000151A (es) Terapia de combinacion de verapamilo y mometasona para el tratamiento de rinosinusitis cronica.